Chest:全国肺部筛查试验中,烟草依赖可预测高肺癌发病死亡率和低戒烟率

2018-05-23 xiangting MedSci原创

TTFC是烟草依赖的单一问题评估,在肺癌筛查时使用TTFC对个体化烟草治疗和改善风险评估有一定意义。

将烟草治疗纳入肺癌筛查项目可能会影响高危吸烟者的戒烟行为。为了更好地了解筛查队列中吸烟者的特征,该研究将这些变量与下游结局相关联,确定了继续吸烟的预测因子。

这项研究是对全国肺部筛查试验随机临床研究的二级分析。烟草依赖通过尼古丁依赖的Fagerstr?m测试、吸烟指数重度和首次吸烟的时间(TTFC)来评估。进行描述性统计。使用描述性统计和根据尼古丁依赖分层的χ2检验评估临床结局(戒烟、肺癌和死亡率)。分别使用Logistic和Cox回归模型研究烟草依赖对戒烟和死亡率的影响。

与低依赖性吸烟者相比,依赖性评分高的患者戒烟可能性较小(TTFC OR,0.50 [95%CI,0.42-0.60])。根据所有3项度量测试的高依赖性指标与临床结局恶化相关。TTFC显示,醒后5分钟内吸烟的患者(表明依赖性高)肺癌发病率(醒后>60分钟为2.07% vs 醒后≤5分钟为5.92%;危险比[HR] 2.56 [95% CI,1.49-4.41]),全因死亡率(>60分钟5.38% vs ≤5分钟为11.21%; HR,2.19 [95%CI,1.55-3.09])和肺癌特异性死亡率(>60分钟为0.55% vs ≤5分钟为2.92%;HR,4.46 [95%CI,1.63-12.21])均较高。

TTFC是烟草依赖的单一问题评估,在肺癌筛查时使用TTFC对个体化烟草治疗和改善风险评估有一定意义。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051150, encodeId=b3b42051150f7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Apr 01 17:03:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799845, encodeId=aa131e998451b, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Oct 11 22:03:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803793, encodeId=bba61803e93c5, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Wed Nov 21 13:03:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929489, encodeId=ddc91929489fc, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Dec 10 16:03:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310200, encodeId=955f1310200c7, content=<a href='/topic/show?id=53036e11185' target=_blank style='color:#2F92EE;'>#烟草#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67111, encryptionId=53036e11185, topicName=烟草)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri May 25 01:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317812, encodeId=097431e812b2, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed May 23 10:10:29 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051150, encodeId=b3b42051150f7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Apr 01 17:03:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799845, encodeId=aa131e998451b, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Oct 11 22:03:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803793, encodeId=bba61803e93c5, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Wed Nov 21 13:03:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929489, encodeId=ddc91929489fc, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Dec 10 16:03:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310200, encodeId=955f1310200c7, content=<a href='/topic/show?id=53036e11185' target=_blank style='color:#2F92EE;'>#烟草#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67111, encryptionId=53036e11185, topicName=烟草)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri May 25 01:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317812, encodeId=097431e812b2, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed May 23 10:10:29 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051150, encodeId=b3b42051150f7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Apr 01 17:03:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799845, encodeId=aa131e998451b, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Oct 11 22:03:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803793, encodeId=bba61803e93c5, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Wed Nov 21 13:03:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929489, encodeId=ddc91929489fc, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Dec 10 16:03:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310200, encodeId=955f1310200c7, content=<a href='/topic/show?id=53036e11185' target=_blank style='color:#2F92EE;'>#烟草#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67111, encryptionId=53036e11185, topicName=烟草)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri May 25 01:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317812, encodeId=097431e812b2, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed May 23 10:10:29 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051150, encodeId=b3b42051150f7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Apr 01 17:03:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799845, encodeId=aa131e998451b, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Oct 11 22:03:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803793, encodeId=bba61803e93c5, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Wed Nov 21 13:03:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929489, encodeId=ddc91929489fc, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Dec 10 16:03:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310200, encodeId=955f1310200c7, content=<a href='/topic/show?id=53036e11185' target=_blank style='color:#2F92EE;'>#烟草#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67111, encryptionId=53036e11185, topicName=烟草)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri May 25 01:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317812, encodeId=097431e812b2, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed May 23 10:10:29 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-12-10 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051150, encodeId=b3b42051150f7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Apr 01 17:03:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799845, encodeId=aa131e998451b, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Oct 11 22:03:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803793, encodeId=bba61803e93c5, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Wed Nov 21 13:03:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929489, encodeId=ddc91929489fc, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Dec 10 16:03:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310200, encodeId=955f1310200c7, content=<a href='/topic/show?id=53036e11185' target=_blank style='color:#2F92EE;'>#烟草#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67111, encryptionId=53036e11185, topicName=烟草)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri May 25 01:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317812, encodeId=097431e812b2, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed May 23 10:10:29 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-25 mnda
  6. [GetPortalCommentsPageByObjectIdResponse(id=2051150, encodeId=b3b42051150f7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Apr 01 17:03:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799845, encodeId=aa131e998451b, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Thu Oct 11 22:03:00 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803793, encodeId=bba61803e93c5, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Wed Nov 21 13:03:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929489, encodeId=ddc91929489fc, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Dec 10 16:03:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310200, encodeId=955f1310200c7, content=<a href='/topic/show?id=53036e11185' target=_blank style='color:#2F92EE;'>#烟草#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67111, encryptionId=53036e11185, topicName=烟草)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri May 25 01:03:00 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317812, encodeId=097431e812b2, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Wed May 23 10:10:29 CST 2018, time=2018-05-23, status=1, ipAttribution=)]
    2018-05-23 明月清辉

    谢谢分享.学习了

    0

相关资讯

Cell Death Dis:HOXA4可能作为肺癌抑癌基因

肺癌是全球癌症相关死亡的主要原因。 最常见的肺癌类型是非小细胞肺癌(NSCLC),约占肺癌病例的85%。大多数肺癌的总生存率相对较低,主要原因是缺乏明显的初始症状和有效的治疗手段。

肺癌微波消融治疗经验分享

在世界范围内,肺癌的发病率和死亡率居癌症之首,全球每年发病约250万例,每年有超过160万人死于肺癌。

CLIN CANCER RES:通过循环肿瘤DNA早期评估肺癌免疫治疗反应

通常通过连续的影像学检测决定需要继续还是中断免疫检查点抑制治疗。但是,由于肿瘤缩小缓慢或由于炎症反应反而出现增大时,免疫治疗反应评估难度较大。CLIN CANCER RES近期发表了一篇文章,研究监测循环肿瘤DNA(ctDNA)水平改变是否可以早期进行免疫治疗效果评估。

Radiology:利用ITK-SNAP基于轮廓快速分割在18F-FDG PET肺癌成像中的应用价值

本研究旨在评价ITK-SNAP软件在FDG PET图像中对不规则肺癌分割的应用价值,并与优化的基于专家的手动分割能力进行比较,研究人员将结果发表在Radiology上。

Sci Rep:与肺癌相关的副肿瘤性边缘叶脑炎

GABAB脑炎患者比经典抗Hu抗体PLE患者对免疫治疗的反应更好。抗癌治疗可以进一步改善神经症状。

AZ的肺癌药物Tagrisso在欧洲获准作为一线用药

欧洲的监管顾问支持阿斯利康公司的肺癌药物Tagrisso作为一线用药的批准。欧洲药品管理局人用药品委员会(CHMP)建议扩大该药品的标签,以包括表皮生长因子受体(EGFR)突变的成人局部晚期或转移性非小细胞肺癌(NSCLC)的成人一线治疗。该研究的首席医疗官Sean Bohen指出:"该积极的建议承认Tagrisso的osimertinib具有欧洲EGFR突变NSCLC患者的一线治疗新标准的潜力。